Investor Overview
Cue Biopharma is a clinical-stage biopharmaceutical company focused on advancing a robust portfolio of therapies aimed at enabling functional cures across allergic and autoimmune diseases.
Our lead asset, CUE-221, is a novel anti-IgE antibody with a dual mechanism of action, currently in Phase 2 development for allergic diseases. In addition, we developed the Immuno-STAT® platform designed to engineer therapies that selectively target disease-specific T cells in vivo without broad immune modulation. CUE-401, our lead asset targeting autoimmune disease was developed using the Immuno-STAT® platform. It is a bifunctional IL-2 and TGF-β molecule advancing towards Phase 1 and was designed to restore immune balance utilizing Treg-mediated tolerance.
Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
Corporate Deck – July 2026
The transcripted remarks made at the Jefferies Healthcare Conference are as of June 3, 2026. Company guidance for CUE-221 Phase 2 data was updated on July 9, 2026, from “in the second half of 2026” to “by the end of the third quarter of 2026”.
News & Press
